Central Neuropathic Pain
13
2
4
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
38%
5 trials in Phase 3/4
100%
5 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (13)
Treating Central Neuropathic Pain With Low Dose Naltrexone for People With Spinal Cord Injury
Nitrous Oxide as Treatment for Fibromyalgia
Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan/Lidocaine Combination Clinical Trial
Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan Dose Response Clinical Trial
Low Intensity Focused Ultrasound Modulation of Thalamic Nuclei for Central Neuropathic Pain.
Study of Mirogabalin for Central Neuropathic Pain
Machine-Learning Based EEG Biomarkers for Personalized Interventions
Efficacy and Safety of HSK16149 Capsule in the Treatment of Moderate and Severe Central Neuropathic Pain in China
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis
Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Efficacy Of Pregabalin In Subjects With Post-Stroke Central Neuropathic Pain
EEG Predictors of Neuropathic Pain in SCI